These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Activation of mammalian target of rapamycin and the p70 S6 kinase by arsenic trioxide in BCR-ABL-expressing cells. Yoon P; Giafis N; Smith J; Mears H; Katsoulidis E; Sassano A; Altman J; Redig AJ; Tallman MS; Platanias LC Mol Cancer Ther; 2006 Nov; 5(11):2815-23. PubMed ID: 17121928 [TBL] [Abstract][Full Text] [Related]
5. Targeting Hedgehog signaling pathway and autophagy overcomes drug resistance of BCR-ABL-positive chronic myeloid leukemia. Zeng X; Zhao H; Li Y; Fan J; Sun Y; Wang S; Wang Z; Song P; Ju D Autophagy; 2015; 11(2):355-72. PubMed ID: 25701353 [TBL] [Abstract][Full Text] [Related]
6. Enhanced Bcr-Abl-specific antileukemic activity of arsenic trioxide (Trisenox) through glutathione-depletion in imatinib-resistant cells. Konig H; Härtel N; Schultheis B; Schatz M; Lorentz C; Melo JV; Hehlmann R; Hochhaus A; La Rosée P Haematologica; 2007 Jun; 92(6):838-41. PubMed ID: 17550858 [TBL] [Abstract][Full Text] [Related]
7. In vitro studies of the combination of imatinib mesylate (Gleevec) and arsenic trioxide (Trisenox) in chronic myelogenous leukemia. La Rosée P; Johnson K; O'Dwyer ME; Druker BJ Exp Hematol; 2002 Jul; 30(7):729-37. PubMed ID: 12135670 [TBL] [Abstract][Full Text] [Related]
8. BCR-ABL mediates arsenic trioxide-induced apoptosis independently of its aberrant kinase activity. Puccetti E; Güller S; Orleth A; Brüggenolte N; Hoelzer D; Ottmann OG; Ruthardt M Cancer Res; 2000 Jul; 60(13):3409-13. PubMed ID: 10910048 [TBL] [Abstract][Full Text] [Related]
9. Multifaceted approach to the treatment of bcr-abl-positive leukemias. O'Dwyer M Oncologist; 2002; 7 Suppl 1():30-8. PubMed ID: 11961207 [TBL] [Abstract][Full Text] [Related]
10. Caveolin-1 contributes to realgar nanoparticle therapy in human chronic myelogenous leukemia K562 cells. Shi D; Liu Y; Xi R; Zou W; Wu L; Zhang Z; Liu Z; Qu C; Xu B; Wang X Int J Nanomedicine; 2016; 11():5823-5835. PubMed ID: 27853367 [TBL] [Abstract][Full Text] [Related]
11. Resveratrol enhances the suppressive effects of arsenic trioxide on primitive leukemic progenitors. Wu EJ; Goussetis DJ; Beauchamp E; Kosciuczuk EM; Altman JK; Eklund EA; Platanias LC Cancer Biol Ther; 2014 Apr; 15(4):473-8. PubMed ID: 24496081 [TBL] [Abstract][Full Text] [Related]
12. VEGF depletion enhances bcr-abl-specific sensitivity of arsenic trioxide in chronic myelogenous leukemia. Luo X; Feng M; Zhu X; Li Y; Fei J; Zhang Y Hematology; 2013 Nov; 18(6):334-40. PubMed ID: 24129092 [TBL] [Abstract][Full Text] [Related]
13. Arsenic trioxide and bortezomib interact synergistically to induce apoptosis in chronic myelogenous leukemia cells resistant to imatinib mesylate through Bcr/Abl‑dependent mechanisms. Xu W; Wei W; Yu Q; Wu C; Ye C; Wu Y; Yan H Mol Med Rep; 2014 Sep; 10(3):1519-24. PubMed ID: 24939418 [TBL] [Abstract][Full Text] [Related]
14. Anti-cancer fatty-acid derivative induces autophagic cell death through modulation of PKM isoform expression profile mediated by bcr-abl in chronic myeloid leukemia. Shinohara H; Taniguchi K; Kumazaki M; Yamada N; Ito Y; Otsuki Y; Uno B; Hayakawa F; Minami Y; Naoe T; Akao Y Cancer Lett; 2015 Apr; 360(1):28-38. PubMed ID: 25644089 [TBL] [Abstract][Full Text] [Related]
15. Inhibition of small GTPase RalA regulates growth and arsenic-induced apoptosis in chronic myeloid leukemia (CML) cells. Zhu X; Li Y; Luo X; Fei J Cell Signal; 2012 Jun; 24(6):1134-40. PubMed ID: 22330069 [TBL] [Abstract][Full Text] [Related]
16. Effect of arsenic trioxide on different cell lines derived from chronic myeloid leukemia. Jing HM; Yukihiro S; Ke XY; Yoshiro K; Akiharu W Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2002 Oct; 10(5):413-8. PubMed ID: 12513739 [TBL] [Abstract][Full Text] [Related]
17. AID expression is correlated with Bcr-Abl expression in CML-LBC and can be down-regulated by As2O3 and/or imatinib. Liu Z; Wu X; Duan Y; Wang Y; Shan B; Kong J; Ma X; Bao Y Leuk Res; 2011 Oct; 35(10):1355-9. PubMed ID: 21570118 [TBL] [Abstract][Full Text] [Related]
18. Arsenic trioxide inhibits translation of mRNA of bcr-abl, resulting in attenuation of Bcr-Abl levels and apoptosis of human leukemia cells. Nimmanapalli R; Bali P; O'Bryan E; Fuino L; Guo F; Wu J; Houghton P; Bhalla K Cancer Res; 2003 Nov; 63(22):7950-8. PubMed ID: 14633726 [TBL] [Abstract][Full Text] [Related]
19. Autophagy enhanced antitumor effect in K562 and K562/ADM cells using realgar transforming solution. Wang X; Chen B; Zhao L; Zhi D; Hai Y; Song P; Li Y; Xie Q; Inam U; Wu Z; Yu L; Li H Biomed Pharmacother; 2018 Feb; 98():252-264. PubMed ID: 29272786 [TBL] [Abstract][Full Text] [Related]
20. [Protein tyrosine kinase (PTK) activities during the induction of apoptosis by arsenic trioxide (As2O3)]. Xiao D; Sun G; Wu W Zhonghua Xue Ye Xue Za Zhi; 1998 May; 19(5):234-6. PubMed ID: 11243118 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]